Corporate information as at 13 Sep 2017

ASX 300 company

ASX code: SPL

US OTCQX code: SPHRY

Share price: A$1.10

Market capitalisation: ~A$400M

Shares outstanding: 369.1M

Cash (at 30 Jun 2017): A$61.8M

Average ASX daily volume: ~650K shares

Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is a global biopharmaceutical company based in Australia with established commercial partnerships and products launched, or nearing commercial launch, across the pharmaceutical and sexual health sectors based on a proprietary dendrimer platform.

Investment Proposition

- **Unique proprietary dendrimer technology platform**
- **Product portfolio targeting large, high value and diversified markets**
- **Proven track record of commercialisation**
  - **VivaGel® condom in-market (Australia & North America)**
  - **VivaGel® BV – treatment product awaiting launch and regulatory approval applications underway for prevention product**
  - **Added significant value to Priostar® (Agrochemicals) portfolio, recently sold to Agrium Inc. for A$35M**
  - **Successful partnership strategy delivering results with several licencing deals and commercial arrangements in place, accelerating path to market and managing investment risk**
- **Well-funded, with existing cash reserves of A$61.8m (as at 30 June)**



VivaGel® BV: breakthrough product for bacterial vaginosis (BV)

VivaGel® BV is a water-based gel, with a novel mechanism of action, which has been successfully developed for two separate indications: ***BV treatment (short-term use)*** and ***prevention of recurrent BV (rBV) (long-term use)***. BV is a serious condition that affects nearly 1 in 3 women in the US, with the majority of patients experiencing recurrence. Current treatments have significant issues and there are no approved products for prevention of rBV.

VivaGel® BV has demonstrated compelling efficacy in phase 3 trials and is an appealing product for patients:

- ✓ Treatment and rapid symptom resolution
- ✓ Targets BV bacteria and has a novel mechanism of action on biofilm
- ✓ Non-antibiotic and not absorbed into the bloodstream (excellent safety and tolerability)

Attractive commercial proposition: Two global markets - estimated to be US$750M for BV treatment and US$1B for prevention of rBV annually.

FDA New Drug Application:

- NDA well-advanced for both indications
- Special Protocol Assessment already in place with the FDA to reduce regulatory risk
- QIDP designation and Fast Track status granted by the FDA

VivaGel® BV already has European marketing approval for the treatment indication.

Extensive partnering discussions: currently underway globally advised by a leading healthcare bank. VivaGel® BV is already licensed to Aspen in Australia and New Zealand with launch planned upon TGA approval.

Company contact information:

Address: 4-6 Southampton Cres, Abbotsford 3067, AUSTRALIA

T: +61 3 8532 2700

Jackie Fairley, CEO
+61 3 8532 2704
jackie.fairley@starpharma.com

Nigel Baade, CFO & Company Secretary
+61 3 8532 2704
nigel.baade@starpharma.com

Rebecca Wilson, Media & IR
WE Buchan
+61 3 8866 1200
rwilson@buchanwe.com.au

VivaGel® condom: World's first and only antiviral Condom

- Condom lubricant contains VivaGel® which has been proven in laboratory studies to inactivate up to 99.9% of HIV, HSV and HPV, which are viruses that cause sexually transmitted infections (STIs)
- VivaGel® condom is available in Australia and Canada under Ansell's Lifestyles® Dual Protect™ brand
- Licensed to Ansell, Okamoto (Japan), Koushan Pharmed (Iran) and Sky & Land (China – for the Government sector – annual government requirement: ~3 billion condoms)
- Advanced regulatory review in other markets

DEP® drug delivery – revolutionary platform

Starpharma's novel DEP® platform has broad commercial applicability in drug delivery by enhancing the performance and reducing the toxicity of existing drugs as well as extending the patent life of existing or new drugs.

Partnered DEP® programs (partner funded)

Starpharma's partnership with AstraZeneca includes a multiproduct DEP® licence which currently involves the development and commercialisation of two novel AstraZeneca oncology compounds with potential to add more. AstraZeneca recently paid Starpharma a US$2M milestone payment for its first DEP® candidate, which was triggered by completing the final preclinical stage, prior to advancing to clinical trials. During 2016, AstraZeneca also initiated another new DEP® drug delivery program for a product in its portfolio - further validation of the value of Starpharma's DEP® platform and its broad application.

"SPL estimates that each product successfully commercialised under this agreement could be worth around US$450m to Starpharma and, depending on the range of indications and degree of commercial success in the market, potentially significantly more." - Jackie Fairley Starpharma CEO

"Achievement of this important development milestone is indicative of the success we have seen in our DEP® program in partnership with Starpharma. It is a highly productive collaboration and the DEP® technology has enabled us to advance a very exciting novel oncology agent towards the clinic. We're continuing to investigate the potential of DEP® more broadly across molecules within our oncology portfolio." - Dr Susan Galbraith, SVP, Head of the Oncology Innovative Medicines Unit at AstraZeneca

Starpharma has also signed two Targeted DEP® partnerships with world leading antibody-drug conjugate companies.

Example of DEP® license - AstraZeneca

- First DEP® candidate receipts est. US$450M (US$126M + royalties)
- Subsequent DEP® candidates US$93M + royalties
- Tiered royalties on net sales on the resultant AstraZeneca DEP® products
- AstraZeneca funds all development and commercialisation costs

Internal DEP® programs

- DEP® docetaxel: enhanced version of anti-cancer drug Taxotere® - modified to reduce side effects such as neutropenia (white blood cell toxicity) and hair loss while enhancing efficacy. Encouraging efficacy signals in a range of cancers emerging from the current Phase 1 trial, and will soon enter Phase 2.
- DEP® cabazitaxel: detergent free version of leading cancer drug Jevtana®. Significantly outperformed Jevtana® in a human breast cancer model with respect to both level and duration of anti-cancer activity and survival, and with superior safety. Phase 1 planned for 2H CY2017.
- DEP® irinotecan: improved version of irinotecan has demonstrated significantly better anti-tumour activity and increased survival compared with irinotecan in a variety of human colon cancer models.
- Targeted DEP®: Starpharma's novel antibody-targeted DEP® conjugate resulted in complete tumour regression and 100% survival in an ovarian cancer model.

Benefits of DEP®

- Improved efficacy
- Reduced toxicity
- Improved pharmacokinetics
- Improved solubility
- Patent life extension

Starpharma's Partners

AstraZeneca · aspen AUSTRALIA · Ansell · okamoto · SKY & LAND · Koushan Pharmed